SparingVision named a ‘Fierce 15’ Company by Fierce Biotech

SparingVision’s lead asset SPVN06 clears IND application in the US for retinitis pigmentosa

SparingVision Raises €75 Million Series B

SparingVision announces strategic collaboration with Intellia Therapeutics

SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics

4BIO Capital leads SparingVision’s €44.5 million financing round